Product datasheet

Anti-VEGF Receptor 2 antibody ab45010

Overview

Product name: Anti-VEGF Receptor 2 antibody
Description: Rabbit polyclonal to VEGF Receptor 2
Host species: Rabbit
Tested applications: Suitable for: IHC-P, WB
Species reactivity: Reacts with: Mouse, Rat, Human, Pig
Immunogen: Synthetic peptide corresponding to Mouse VEGF Receptor 2 aa 1-50. 50 amino acid range maps within amino acids 1-50 VEGF
Positive control: Hey cells. Angiosarcoma.

Properties

Form: Liquid
Storage instructions: Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage buffer: pH: 7.40
Preservative: 0.1% Sodium azide
Constituent: 0.01% PBS
Purity: Protein G purified
Clonality: Polyclonal
Isotype: IgG

Applications

Our Abpromise guarantee covers the use of ab45010 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

<table>
<thead>
<tr>
<th>Application</th>
<th>Abreviews</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHC-P</td>
<td>★★★★☆☆</td>
<td>1/50.</td>
</tr>
<tr>
<td>WB</td>
<td></td>
<td>1/1000. Predicted molecular weight: 150 kDa.</td>
</tr>
</tbody>
</table>
### Target

| **Function** | Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. |
| **Involvement in disease** | Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. |
| **Sequence similarities** | Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. \nContains 7 Ig-like C2-type (immunoglobulin-like) domains. \nContains 1 protein kinase domain. |
| **Post-translational modifications** | Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. |
| **Cellular localization** | Membrane. |

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

### Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit [https://www.abcam.com/abpromise](https://www.abcam.com/abpromise) or contact our technical team.

### Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors